SCHEMBL2526356

SCHEMBL2526356

O=C(O)c1cn(C2CC2)c2c3c(c(F)cc2c1=O)N1C[C@](O)(COc2ccc(N4CC(COC(=O)C5CCNCC5)OC4=O)cc2F)C[C@H]1CO3

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.36
ALDH1A1 P00352 6/20 0.36
HPGD P15428 5/20 0.36
HSD17B10 Q99714 5/20 0.36
KCNH2 Q12809 4/20 0.36
POLB P06746 3/20 0.36
OPRM1 P35372 2/20 0.36
PRKD3 O94806 1/20 0.36
ALOX15 P16050 1/20 0.36
CLK2 P49760 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ALB P02768 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
AADAT Q8N5Z0 2/20 0.35
TUBB4A P04350 1/20 0.35
TUBB P07437 1/20 0.35
TUBA3C P0DPH7 1/20 0.35
TUBA1B P68363 1/20 0.35
TUBA4A P68366 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2526348 1.00 KDM4E (0.36) KDM4EALDH1A1HPGDHSD17B10KCNH2
SCHEMBL583932 0.91 KCNH2 (0.39) KDM4EALDH1A1HPGDHSD17B10KCNH2
SCHEMBL583933 0.91 KCNH2 (0.39) KDM4EALDH1A1HPGDHSD17B10KCNH2
SCHEMBL584018 0.90 KCNH2 (0.40) KDM4EALDH1A1HPGDHSD17B10KCNH2
SCHEMBL583757 0.90 KCNH2 (0.40) KDM4EALDH1A1HPGDHSD17B10KCNH2
SCHEMBL583756 0.90 KCNH2 (0.40) KDM4EALDH1A1HPGDHSD17B10KCNH2
Hydrochloric Acid SCHEMBL584348 0.89 KCNH2 (0.40) KDM4EALDH1A1HPGDHSD17B10KCNH2
Hydrochloric Acid SCHEMBL584349 0.89 KCNH2 (0.40) KDM4EALDH1A1HPGDHSD17B10KCNH2
SCHEMBL584758 0.89 KCNH2 (0.36) KDM4EALDH1A1HPGDHSD17B10KCNH2
SCHEMBL585002 0.89 KCNH2 (0.36) KDM4EALDH1A1HPGDHSD17B10KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8039466-B2 5-hydroxymethyl-oxazolidin-2-one antibacterials ACTELION PHARMACEUTICAL LTD. (CH) 2011-10-18 US claimed
US-20100069376-A1 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS ACTELION PHARMACEUTICALS, LTD. (CH) 2010-03-18 US claimed
US-8039466-B2 5-hydroxymethyl-oxazolidin-2-one antibacterials ACTELION PHARMACEUTICAL LTD. (CH) 2011-10-18 US disclosed
US-20100069376-A1 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS ACTELION PHARMACEUTICALS, LTD. (CH) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069376-A1 5-HYDROXYMETHYL-OXAZOLIDIN-2-ONE ANTIBACTERIALS OGFOD1, ODC1, OXGR1 KDM4E 1273/4885ALDH1A1 698/4885HPGD 1938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.